Match tier
Listed
Presence
Current · Arkansas
Last published
2023
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
E
Erming Tian
High Impact
Researcher
Also affiliated: University of Maryland, Baltimore (2003); Hackensack University Medical Center (2003); Medical College of Wisconsin (2003); Norwegian University of Science and Technology (2006–2016); Cornell University (2001); University of Arkansas Medical Center (2016–2018); Saint Vincent Health System (2003); Cancer Research And Biostatistics (2003); St Olav's University Hospital (2007); Winthrop Rockefeller Foundation (2019–2023); National Cancer Institute (2001)
Faculty Researcher
31 h-index
102 pubs
5,437 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Erming Tian's research focuses on multiple myeloma, a cancer of plasma cells. His work investigates genetic alterations and their correlation with clinical outcomes in patients with this disease. Publications detail the implications of specific chromosomal changes, such as the deletion of 1p13.3 and gain of 1q21, on patient prognosis. Tian also examines minimal residual disease (MRD) negativity in bone marrow, exploring its significance for long-term outcomes and identifying persistent MRD as a high-risk feature.
Further research areas include the phenotypic markers used in flow cytometry for assessing disease progression in monoclonal gammopathy of unknown significance and the bone remineralization of lytic lesions in multiple myeloma patients. Tian's work has involved collaborations with Shmuel Yaccoby, Michele Cottler‐Fox, Clyde Bailey, and Susan Panozzo at the University of Arkansas for Medical Sciences. He leads a research group and has an h-index of 31 with over 5,403 citations.
Metrics
- h-index: 31
- Publications: 102
- Citations: 5,437
Selected Publications
-
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma (2023)
-
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma (2021)
-
Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma (2021)
-
Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience (2021)
-
Innate Biomineralization (2020)
-
Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome (2019)
-
An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome (2019)
-
Identification of novel breakpoints for locus- and region-specific translocations in 293 cells by molecular cytogenetics before and after irradiation (2019)
-
Microhomology-mediated end joining drives complex rearrangements and overexpression of <i>MYC</i> and <i>PVT1</i> in multiple myeloma (2019)
-
Microhomology-mediated end joining drives complex rearrangements and over-expression of <i>MYC</i> and <i>PVT1</i> in multiple myeloma (2019)
-
An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome (2018)
-
Fluorescence In Situ Hybridization (FISH) in Multiple Myeloma (2018)
-
<i>MYC</i> Rearrangements in Multiple Myeloma Are Complex, Can Involve More Than Five Different Chromosomes, and Correlate with Increased Expression of <i>MYC</i> and a Distinct Downstream Gene Expression Pattern (2017)
-
Chromosome 1q12 Instability Drives Both 1q21 Amplification and Arm-Length Deletions in Multiple Myeloma (2017)
-
Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status (2017)
Collaboration Network
Top Collaborators
Meera Mohan
Medical College of Wisconsin (US)
4 shared publications
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
Frits van Rhee
Winthrop Rockefeller Foundation
4 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
Sharmilan Thanendrarajan
Winthrop Rockefeller Foundation
4 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
Carolina Schinke
Winthrop Rockefeller Foundation
4 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
Maurizio Zangari
Winthrop Rockefeller Foundation
4 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
Daisy Alapat
University of Arkansas for Medical Sciences
3 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
Anikó Szabó
Medical College of Wisconsin (US)
2 shared publications
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
Naveen Yarlagadda
2 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
Samantha Kendrick
University of Arkansas for Medical Sciences
2 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
Jeffrey R. Sawyer
University of Arkansas for Medical Sciences (US)
2 shared publications
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
Guido Tricot
University of Arkansas for Medical Sciences
2 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
Manoj Kumar
University of Arkansas for Medical Sciences (US)
1 shared publication
- Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience
Rohan Samant
University of Arkansas for Medical Sciences (US)
1 shared publication
- Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience
Rudy Van Hemert
University of Arkansas for Medical Sciences
1 shared publication
In database
- Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience
Shivang Desai
University of Arkansas for Medical Sciences (US)
1 shared publication
- Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience
Similar Researchers
Based on overlapping research topics
Christopher P. Wardell
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Genomics and Diagnostics
Disease Mechanisms Research
Syeda Naqvi
University of Arkansas at Fayetteville
Bone health and treatments
Disease Mechanisms Research
Metabolism and Genetic Disorders
Jomeeka Meeks
University of Arkansas for Medical Sciences
Bone health and treatments
Disease Mechanisms Research
Metabolism and Genetic Disorders
David E. Mery
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Disease Mechanisms Research
Metabolism and Genetic Disorders
Bart Barlogie
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Disease Mechanisms Research
Metabolism and Genetic Disorders
Jillian Hackney
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Bone health and treatments
Disease Mechanisms Research